Preparation, In Vivo Administration, Dose-Limiting Toxicities, and Antineoplastic Activity of Cytochalasin B

Matthew Trendowski, Joseph N. Zoino, Timothy D. Christen, Christopher Acquafondata and Thomas P. Fondy
Department of Biology, Syracuse University, 107 College Place, Syracuse, NY 13244, USA

Abstract
An effective and inexpensive protocol for producing cytochalasins A and B is being disclosed to propose a viable method by which to examine the in vivo antineoplastic activity of these congeners in preclinical tumor-bearing mammalian models. In addition, we determine the maximum tolerated doses of cytochalasin B using multiple routes and formulations, characterize the tissue distribution of intravenous bolus cytochalasin B, and assess the in vivo antineoplastic activity of cytochalasin B in comparison in doxorubicin in Balb/c mice challenged intradermally with M109 murine lung carcinoma. We also examine the effects of cytochalasin B against several other murine neoplastic cell lines (Lewis lung, LA4, B16F10, and M5076). Finally, we examine a potential mechanism of the antimetastatic activity of cytochalasin B by observing the effects of the agent on the secretion of N-acetylglucosaminidase (GlcNACase) by B16BL6 and B16F10 murine melanomas in vitro. The results of the study can be summarized as follows: 1) Cytochalasin B can be safely administered intravenously, intraperitoneally, and subcutaneously in murine models, with the maximum tolerated dose of all routes of administration being increased by liposome encapsulation. 2) Cytochalasin B can significantly inhibit the growth of tumors in mice challenged with M109, Lewis lung, LA4, B16F10, or M5076, producing long-term survival against lung carcinomas and adenocarcinomas (M109, Lewis lung, and LA4) and B16F10 melanoma, but not M5076 sarcoma. These effects were comparable to intraperitoneally administered doxorubicin. 4) Low concentrations of cytochalasin B inhibit the secretion of GlcNACase, indicating that cytochalasin B may inhibit metastatic progression by mechanisms not directly associated with its influence on cell adhesion and motility.

Introduction
Microtubule-directed agents have long been used in cancer chemotherapy because of their ability to interfere with chromosome congression and the proper segregation of chromosomes, thereby invoking G2/M arrest and other aberrant characteristics that eventually potentiate apoptosis. In addition to these traditional mitotic inhibitors, cell biology studies have elucidated a tremendous diversity of cytoskeletal-directed agents that affect the two other components of the cytoskeleton (microfilaments and intermediate filaments), many of which exert potent antineoplastic activity [1]. However, despite this diversity of cytoskeletal-directed agents available to oncologists, all currently approved cytoskeletal-directed agents used in the clinic have microtubule-based mechanisms [1]. Although it is true that these compounds act by distinct mechanisms (epothilones and taxanes stabilize microtubules, whereas eribulin and vinca alkaloids disrupt polymerization), they all are microtubule directed and target nuclear DNA replication in dividing cells.

It has been demonstrated that substantial differences exist between the microfilament biochemistry of normal cells and their neoplastic counterparts [1–3] and that these differences affect not only nuclear
division but also cytokinesis, cell size and shape, cell attachment and detachment, and cell motility. These diverse cellular properties affected by actin polymerization suggest that agents affecting microfilament biochemistry should elicit notable antineoplastic activity as single agents and in combination with other agents and treatment modalities.

Cytochalasins are mycogenic toxins known to disrupt the formation of filamentous (F)-actin and, in some cases, prevent the formation of F-actin in treated cells altogether, thereby precluding the crucial cellular functions of microfilaments [4–6]. More than 60 different cytochalasins from several species of fungi have been classified, and most appear to markedly affect actin polymerization [1,5,7,8]. However, the most studied congener in regard to antineoplastic activity has been cytochalasin B. As a microfilament-disrupting agent, cytochalasin B alters many facets of cell physiology dictated by F-actin, including cell motility, adherence, secretion, drug efflux, deformability, morphology, and size, among many other cellular properties [4,6,9]. Because of the importance of microfilaments in the formation and ingestion of the cleavage furrow, cytochalasin B is a potent inhibitor of cytokinesis and has been shown repeatedly to selectively enlarge and multinucleate neoplastic cells [10–14]. Such cells are ideal targets for microtubule-directed and nucleic acid–directed agents, and drug synergy has been noted between cytochalasin B and clinically approved antineoplastic agents that act through these mechanisms [15–17]. Further, we have shown that many cytochalasin congeners inhibit ATP binding cassette transporter-mediated efflux (manuscript under review), tentatively suggesting that cytochalasins and potentially other microfilament-directed agents may be used to treat cancers refractory to normal chemotherapy because of ATP binding cassette transporter-related drug resistance.

In addition to our in vitro work, we have extensively characterized the in vitro activity of cytochalasin B against solid tumors and disseminated cancers of murine origin [17–19]. Not only does cytochalasin B significantly improve the lifespan of mice challenged with lung carcinoma, melanoma, or leukemia, but long-term survival is frequently observed [17–19]. Interestingly, cytochalasin B appears to have notable efficacy against highly metastatic cell lines, having higher in vitro cytotoxicity against cell lines selected for metastatic propensity than for the original parental cancer cell line. In addition, cytochalasin B substantially reduces the extent of metastases found in challenged mice [17–19]. These observations are in accordance with the mechanistic studies of cytochalasin congeners, as functioning microfilaments are essential for neoplastic cell motility, invasion, and metastasis [20–24].

Due to the potential clinical importance that cytochalasin B and other microfilament-directed agents may have and the large quantities of these highly expensive agents needed for preclinical and clinical study, we are disclosing our method of producing gram quantities of cytochalasin B from Drechslera dematioidea so that interested laboratories can reproduce and extend our findings. This purification process also produces a smaller amount of cytochalasin A, which demonstrates marked antineoplastic activity against drug-sensitive and resistant SK human ovarian carcinoma cell lines in vitro (manuscript under review). In addition, we provide data relevant for characterizing the tissue distribution of cytochalasin B administered as an intravenous (i.v.) bolus dose. We also examine the routes of administration and the maximum tolerated doses (MTDs) of cytochalasin B in multiple murine models. This analysis includes cytochalasin B that has been liposome encapsulated, as we have previously shown that this formulation reduces cytochalasin B–associated immunosuppression while retaining marked antitumor activity [19]. We then extend our previous in vivo findings by examining the effects of a well-tolerated i.v. treatment protocol of cytochalasin B in comparison with intraperitoneally (i.p.) administered doxorubicin against M109 murine lung carcinoma growing as an intradermal (i.d.) nodule in Balb/c mice. In addition, we investigate the ability of subcutaneous (s.c.) cytochalasin B to potentiate long-term survival (at least 53 days) in mice challenged with the following murine neoplastic cell lines: M109 lung carcinoma, Lewis lung carcinoma, LA4 lung adenocarcinoma, B16F10 melanoma, and M5076 sarcoma. Finally, we characterize a potential mechanism regarding how cytochalasin B reduces the number of metastases found in treated mice by assessing the in vitro effects of the agent on the secretion of N-acetylgalactosaminidase (GlcNACase) by B16BL6 and B16F10 melanoma cell lines.

Materials and Methods

Preparation of Agar and Media Used to Subculture D. dematioidea for Inoculation of Large Mattes

Stocks of D. dematioidea (strain: IMI 74812) were acquired commercially (ATCC 24346). Stocks were grown on slants of potato dextrose agar and yeast extract (PDY). PDY was prepared in 250-ml aliquots using 7.5 g potato dextrose agar, 1.25 g yeast extract, and 250 ml deionized, distilled water. The mixture was heated to near boiling on a water bath while being magnetically stirred until all of the solute dissolved. Five milliliters of PDY was added to 15-mm screw top test tubes (8 ml for 18-mm tubes). The tubes were then autoclaved for 30 minutes at a slow cooling rate (liquid cool) before the tubes were slanted so that the media did not reach more than halfway up the tube. The slants were then cooled, placed in an upright position, and inoculated with D. dematioidea.

Growth of Large Mold Mattes of D. dematioidea

To prepare the growth media (Tanenbaum medium), 10 g bacto soytone, 40 g dextrose, 20 g yeast extract, 150 g sucrose, and 1 l tap water were added to a 2-l Erlenmeyer flask and then magnetically stirred. Five-hundred-milliliter aliquots of media were then transferred to a large Pyrex dish. Media were then supplemented with 5 crumbled Shredded Wheat biscuits spread evenly across the dish. Each dish was then covered with a double layer of aluminum foil and autoclaved for 90 minutes at a slow cooling rate. This process was then repeated to acquire 2-l Tanenbaum medium.

Mattes of D. dematioidea used for cytochalasin preparation were grown in Tanenbaum medium using mold stocks that were the lightest in color as they were the healthiest. Two to three PDY slants were used to inoculate every 500 ml of Tanenbaum medium (2 l total). Mattes were allowed to grow for 15 days on tissue culture plates (20 mm × 245 mm × 245 mm) before being harvested for cytochalasin preparation.

D. dematioidea is a Level 1 Biosafety agent and can be handled with routine sterile procedures and protection from inhalation and exposure to the eyes. Potential allergic responses to high levels of mold spores encountered should be considered, and procedures should be in place to manage any such occurrences.

MeOH Extraction of D. dematioidea

A total of 1.35 kg (wet weight) of healthy mold mattes were lyophilized to acquire 420 g of dry mold. The mold was then blended
with 5 ml MeOH per gram of mold under N₂ gas for 1 minute before being vacuum filtered. The fraction was collected and then set aside. The process was then repeated but only with enough MeOH to put the mold into suspension. The first and second filtrates were then combined to give a total volume of 3 to 4 l. Regular-phase thin layer chromatography (85:15 toluene:MeOH eluent) was used to determine the composition and purity of this crude extract against a small amount of commercially purchased cytochalasin B (Sigma-Aldrich Corp., St. Louis, MO). Water was then added to the filtrates to obtain an 80:20 H₂O:MeOH mixture, bringing the total volume to 12 to 16 l.

Reversed-Phase Thin Layer Chromatography to Acquire Purified Cytochalasin Extract

The 80:20 H₂O:MeOH eluate was subjected to reversed-phase thin layer chromatography with 50 g octadecyl carbon chain (C18)-bonded silica gel mixed with 100 ml MeOH. The column was then air dried for 2 minutes under water aspiration before the column was placed in a desiccator with P₂O₅ and vacuum pumped overnight. The column was then washed with 100 ml hexane before a 200-ml hexane/200-ml 60:40 THF:hexane mixture was used to elute cytochalasin B from the column; eluate was collected as 10-ml fractions. Commercially purchased cytochalasin B was again used to assess the purity of the product using regular-phase thin layer chromatography. Filtrates were then vacuum filtered to acquire precipitant, which was then stored in a dessicator with P₂O₅.

Purification of Cytochalasin Crystals Using Flash Chromatography

Cytochalasin B crystals were dissolved in THF and subjected to flash chromatography using a 150-g silica, 150-ml 1:1 EtOAc:hexane slurry and 350 ml 1:1 EtOAc:hexane as the eluent. Thirty 10-ml fractions were collected and stored at 4°C overnight before being vacuum filtered to collect precipitates. Cytochalasins A and B were then separated using Whatman preparative thin layer chromatography plates (Fisher Scientific International Inc., Hampton, NH). Two distinct bands were then observed, indicating that cytochalasin A (top band) had separated from cytochalasin B (bottom band). These bands were then eluted from the silica using 2 to 3 ml MeOH at a time. The purity of cytochalasins A and B was analyzed using ¹H NMR spectroscopy (spectra not shown). The steps necessary for successful extraction and purification of cytochalasins A and B from mattes of *D. dematioidea* are succinctly highlighted in Figure 1.

Cytochalasin B and Doxorubicin Formulation and Administration

Cytochalasin B was prepared in suspension form in 2% carboxymethyl cellulose 1% Tween 20 (CMC/Tw) and in solution in dimethyl sulfoxide (DMSO) and 33% ethanol:0.9% NaCl solution as previously described [17–19]. In addition, cytochalasin B was liposome encapsulated in unilamellar vesicles of egg phosphatidylcholine:dipymistrophosphatidylglycerol using methods previously described [19]. Doxorubicin was prepared in solution using the 33% ethanol:0.9% NaCl solution.

Suspension formulations of cytochalasin B required that the agent was emulsified in the CMC/Tw vehicle. This was accomplished by dissolving 1 ml Tween 20 into 90 ml pyrogen-free water before adding 2 g carboxymethyl cellulose sodium salt. The mixture was stirred with a magnetic stirrer for ~1 hour before being added to 9 ml distilled water to make a 2% carboxymethyl cellulose/1% Tween 20 vehicle. Cytochalasin B was then added to a sterile plastic syringe before CMC/Tw was added to a second syringe. The hubs of a 22-gauge emulsifying needle were attached to each syringe. The vehicle was a 22-gauge needle, the suspension was passed through a 25-gauge needle with an air bubble of ~0.5 ml kept in the storage syringe to reemulsify the agent and then reemulsified through a 25-gauge needle before being capped before use.

Preparation of Cytochalasin B with ³H-Labeled Phenylmethyl Group

³H-labeled cytochalasin B was prepared to determine the distribution of the agent in Balb/c mice, as assessed by high-performance liquid chromatography (HPLC). Before the inoculation...
of Tanenbaum medium with D. dematioidea, the medium was supplemented with 2 mCi [3H] phenylalanine (side chain 3H, 15 Ci/mol, in sterile ethanol:water, from ICN) in 500 mL of medium, along with one crushed wheat biscuit. The purified product was again subjected to preparative thin layer chromatography in reduced light and was eluted with methanol before use to prevent the formation of cytochalasin A over time.

Conversion of M109 to Continuous Culture (M109c)

M109 murine lung carcinoma cells were converted to continuous culture using methods previously described [17]. As in the previous papers of this series [17–19], comparison between animals challenged i.d. with M109c cells and matched groups challenged with in vivo passaged M109 cells showed that the challenges were indistinguishable in terms of growth kinetics, invasion, metastasis, and host survival.

Solid Tumors In Vivo

M109 murine lung cancer cells were obtained from early s.c. tumor in vivo passaged donors (M109) or from continuous cultures of M109 lung carcinoma cells (M109c). Tumor growth was monitored by daily caliper measurements, which were facilitated by the localized growth of the i.d. challenge contained entirely in a region initially free of hair. Effects on primary tumor appearance, growth rate, invasion, and metastases to the lungs, liver, kidneys, pancreas, and spleen were determined as previously detailed for s.c. challenges with M109 tumor [18].

The other solid tumor lines (Lewis lung, LA4, B16F10, and M5076) were given as a 1 × 10^6 cell challenge s.c. in Balb/c, C57BL/6, or B6D2F1 mice. The procedures for measuring tumor growth were the same as with M109 lung carcinoma.

Statistics

Survival analysis used the Cox-Mantel test as described by Lee [26]. Effects on tumor growth rates were evaluated by repeated-measures analysis of variance using SAS (Cary, NC) software. Tests of hypotheses for between-subject effects were applied, and of time versus group interactions using the Geisser-Greenhouse adjustment in cases where tests of orthogonal components showed absence of sphericity. Differences in lung metastases between treated and control groups were evaluated with a Student-Fisher t test.

Analysis of N-Acetylglucosaminidase Activity in B16BL6 and B16F10 Murine Melanomas after Administration of Cytochalasin B

B16BL6 and B16F10 murine melanomas were cultured using methods previously described [17,19]. Cells were subcultured when they reached 1 × 10^6 cells/ml. The confluent monolayer was treated with 0.2% trypsin-EDTA solution 10× (Sigma-Aldrich Corp.) for 1 minute at 37°C, and the suspended cells were seeded at 4 × 10^4 cells/cm^2 in 25-cm^2 culture flasks. Cells were allowed to attach before being treated with 0.1 or 1 μM cytochalasin B for 48 hours. GlcNACase activity of untreated and cytochalasin B-treated cells was assessed as previously described [27].

Results

Preparation of Cytochalasins A and B

Procedures shown in Figure 1 produced 700 mg of HPLC-pure cytochalasin B and 90 mg of HPLC-pure cytochalasin A. Purity was >99%. Rf values corresponded to commercially obtained congeners, and 1H NMR spectra were in accordance with expected peak values. Crystalline cytochalasin B had a melting point of 216°C to 218°C (commercial cytochalasin B: 217°C to 220°C; literature reference melting points range from 215°C to 223°C) and showed no evidence of fluorescence quenching, iodine vapor positive contaminants, or p-anisaldehyde–positive contaminants when 100 μg was analyzed by thin layer chromatography, indicative of a highly pure product. The radioactive labeling procedure produced 30 mg 3H-labeled cytochalasin B at the phenylmethyl group that was >99% pure as assessed by analytical thin layer chromatography, radiochromatography, and 1H NMR spectroscopy. Specific activity was 3 μCi/mmol.

Tissue Distribution of Intravenously Administered Cytochalasin B in Balb/c Mice

3H-labeled 3.5 mg/kg cytochalasin B was administered as an i.v. bolus dose in Balb/c mice at time 0 and followed over the course of 720 minutes. The total dose per mouse was 70 μg (3.5 μg/g). Tissue distribution revealed that the agent has a marked affinity for the intestines, as 8.75 μg/g tissue was present 30 minutes postinjection and 1.5 μg/g tissue remained after 180 minutes (Figure 2A). Furthermore, it appears that cytochalasin B remains in the intestines for some time, as 0.58 μg/g tissue remained after 720 minutes (Figure 2A). The 6 tissues out of the 12 analyzed that had the highest levels of cytochalasin B at time 0 or at 15 minutes after i.v. treatment are shown in Figure 2A. The five highest concentrations at 15 minutes were in the liver, lungs, intestines, pancreas, and tail (2.8 to 4 μg/g tissue). The kidneys had an initial concentration of 3 μg/g at the time of injection, but showed only 0.4 μg/g at 15 minutes. The six tissues with the lowest distributions at 15 or 30 minutes included the heart, ovaries, spleen, bladder, and stomach. Very little cytochalasin B was detected in the brain initially (0.25 μg/g tissue) or at any time from 15 to 180 minutes (Figure 2A). Interestingly, tissues appeared to follow two types of distribution; either cytochalasin B reached peak concentrations shortly after administration, followed by a gradual decrease (liver, tail, lungs, kidneys, and pancreas), or cytochalasin B concentrations spiked at 30 minutes, followed by a gradual decrease (intestines, heart, spleen, ovaries, and bladder).

Analysis of cytochalasin B tissue distribution was then extended to 24 hours using a 5-mg/kg i.v. bolus dose, which is equal to 5 μg/g, or a 100-μg total dose for a 20-g mouse (Table 1). Interestingly, the concentration of cytochalasin B in the lungs was markedly increased with this higher dose at 30 minutes (0.8 μg/g tissue with 3.5 mg/kg and 11.1 μg/g tissue with 5 mg/kg). In addition, the plasma concentration of cytochalasin B steadily declined over the course of 24 hours, and it appears that the t/2 of an i.v. bolus dose in the blood is between 0.5 and 12 hours in Balb/c mice. The highest tissue concentrations at 30 minutes in Table 1 were recorded in the lungs, intestines, and liver (3 μg/g to 11 μg/g), in agreement with observations made in Figure 2A for the six highest tissues. The heart, spleen, ovaries, kidney, bladder, and stomach were among the tissues with the lowest distribution at 30 minutes in Table 1, again consistent with observations in these tissues for a lower dose of cytochalasin B shown in Figure 2A. Table 1 also shows tissue
distributions to renal lipids, lymph nodes, and thymus that were not examined among the 12 tissues shown in Table 1. It is important to note that, even at this higher concentration of cytochalasin B, concentrations in the brain never rose above 0.08 μg/g tissue. The potential therapeutic implications of this observation will be elaborated upon in the discussion.

When Balb/c mice were challenged i.d. with M109 lung carcinoma and treated with 3.5 mg/kg i.v. bolus cytochalasin B, the agent appeared to have affinity for the tumor that was in the range exhibited in Figure 2A and Table 1 by normal tissues with intermediate cytochalasin B distribution such as the bladder, lymph nodes, thymus, kidney, ovaries, spleen, and heart (Figure 2B). Peak cytochalasin B concentration in the tumor nodule was 0.68 μg/g tissue 5 minutes postinjection and remained above 0.55 μg/g for at least 30 minutes. As with normal tissue, the concentration of cytochalasin B appeared to gradually decrease between 180 and 720 minutes, demonstrating that the agent remains in neoplastic tissue for at least 12 hours after i.v. bolus administration. A concentration of 0.2 μg cytochalasin B/g tumor at 3 hours corresponds to a concentration of 50 μM cytochalasin B, assuming a 1-ml volume/g tumor. This is ~25-fold higher than the bioactive concentration of cytochalasin B in vitro against M109c lung carcinoma at 3 hours [17].

Maximum Tolerated Dose of Cytochalasin B Using Various Routes of Administration and Formulations in Multiple Murine Models

The MTDs of cytochalasin B in suspension, solution, or liposome encapsulation administered i.p., i.v., or s.c. in Balb/c, B6D2F1,
Effects of Intravenously Administered Cytochalasin B and Intraperitoneally Administered Doxorubicin on M109c Murine Lung Carcinoma Challenged Mice

Administration of cytochalasin B as a 5-mg/kg/day i.v. bolus dose on days 1 to 5 to Balb/c mice challenged i.d. with \(2 \times 10^5\) M109c cells appeared to markedly perturb tumor growth (Figure 3A). At 30 days postchallenge, cytochalasin B–treated mice had a mean tumor volume of 0.53 cm\(^3\) (standard error of the mean; SEM = 0.04), whereas mice treated with the vehicle had a mean tumor volume of 0.9 cm\(^3\) (SEM = 0.034). Doxorubicin administered as a 5-mg/kg i.p. dose once or twice had a notable antitumor effect, but it was not as pronounced as cytochalasin B (Figure 3A). These effects on tumor growth appear to be supported by the long-term survival potentiated by the 5-mg/kg/day i.v. bolus cytochalasin B treatment protocol (Figure 3B). There was a 50% survival rate at least up to day 53 for mice challenged with an i.d. tumor nodule in the cohort treated five times with 5-mg/kg i.v. bolus cytochalasin B (n = 16). This is a highly significant prolonging of life expectancy, as all mice treated with the vehicle were dead by day 42 (n = 10). By contrast, mice treated once with 5 mg/kg i.p. doxorubicin were all dead by day 50 (n = 10), and only 1 in 10 mice treated twice with 5 mg/kg i.p. doxorubicin was alive after 53 days. These data are further supported by a Cox-Mantel test that indicated a \(P < .05\) for each treatment cohort.

In addition, the same dose of cytochalasin B markedly reduced the extent of terminal lung metastases observed in Balb/c mice challenged with a single i.d. tumor inoculation (Figure 3C). As previously mentioned [19], mice challenged i.d. with M109c lung carcinoma present significant metastases only in the lungs. The effects of cytochalasin B on reduction in lung metastases appear to be dose dependent, as demonstrated when the 5-mg/kg i.v. bolus dose was administered daily one to five times (Figure 3C). Mice bearing an i.d. tumor and treated with 1, 2, 3, 4, or 5 peritumoral doses of cytochalasin B showed a clear dose-dependent response with a 90% reduction in lung metastases at the terminal stages in the mice receiving five doses of cytochalasin B peritumorally. The cohort of mice treated with i.v. cytochalasin B 5 mg/kg/day for 5 days had a mean of seven nodules (SEM = 2.8), whereas the cohort treated with the vehicle only had a mean of 62 nodules (SEM = 5.4). These effects on terminal lung metastases were significantly different compared with the two doxorubicin cohorts, as mice treated with 5 mg/kg i.p. doxorubicin on day 1 had a mean of 57 nodules (SEM = 3.2), whereas those treated with the same dose on days 1 and 3 had a mean of 50 nodules (SEM = 4.9).

Effects of Cytochalasin B on Prolonging the Survival of Mice Challenged with Various Solid Tumors

Cytochalasin B administered s.c. as a 100-mg/kg dose on day 1 appeared to have marked antineoplastic activity against most of the solid tumor challenges (Figure 4), as a significant proportion of the mice lived at least 53 days after the initial tumor challenge: M109 lung carcinoma (4/10 mice), Lewis lung carcinoma (5/10 mice), LA4 lung adenocarcinoma (6/10 mice), and B16F10 melanoma (4/10 mice). Although 100 mg/kg cytochalasin B s.c. significantly prolonged the survival of mice challenged with M5076 sarcoma in comparison with the vehicle-only treated mice, all mice in this cohort were dead by day 30; the treatment was unable to produce any long-term survivors at day 53 (0/10 mice), and all mice were dead by day 44 (Figure 4).

Effects of Cytochalasin B on N-Acetylglucosaminidase Activity in B16BL6 and B16F10 Murine Melanomas

Before administration of cytochalasin B, B16BL6 and B16F10 melanomas had an extracellular percentage of GlcNACase compared with total enzyme activity ranging from 27% to 41% (Table 3). A total of 0.1 \(\mu\)M cytochalasin B administered for 48 hours decreased this range to 23% to 28%. One micromolar of cytochalasin B administered for the same length of time further reduced this range to 23% to 28%. One micromolar of cytochalasin B administered for the same length of time further reduced this range to 12% to 27%. Interestingly, cytochalasin B appeared to have no influence on the total amount of GlcNACase in either cell line, suggesting that cytochalasin B may inhibit the secretion of GlcNACase and potentially other glucosaminidases. The importance of inhibiting the secretion of glucosaminidases in neoplastic cells will be elaborated upon in the discussion.

Discussion

In the present study, we have demonstrated that cytochalasin B can be safely given to murine models through multiple routes of administration. As previously shown [17, 18], cytochalasin B can be administered i.p., i.v., and s.c. in Balb/c mice, with the MTD being higher using a suspension (CMC/Tw) rather than solution vehicle.

| Route | Vehicle | Formulation | Schedule (Days) | mg/kg | Max. Wt. Loss (%) | Drug Deaths |
|-------|---------|-------------|-----------------|-------|-------------------|-------------|
| l.p.  | CMC/Tw  | Suspension  | 1               | 50    | 7                 | 2/34        |
| CMC/Tw | Suspension | 1, 4, 7    | 50/day          | 6     | 0/16              |             |
| DMSO  | Solution | 2           | 25              | 2     | 1/5               |             |
| CMC/Tw | Liposome | 1           | 400             | 2     | 0/40              |             |
| s.c.  | CMC/Tw  | Suspension  | 1               | 100   | 3                 | 0/31        |
| CMC/Tw | Suspension | 1          | 150             | 7     | 4/28              |             |
| DMSO  | Solution | 1           | 100             | 7     | 5/32              |             |
| CMC/Tw | Liposome | 1           | >500            | 7     | 0/25              |             |
| i.v.  | CMC/Tw  | Suspension  | 1               | 20    | 1                 | 0/10        |
| ErOH/Sal | Solution | 1         | 10-20           | 1-2   | 1/20              |             |
| CMC/Tw | Liposome | 1           | 25              | 1     | 0/10              |             |

Max. Wt. Loss: maximum weight loss experienced after receiving the indicated dose.

* CD2F1 mice could only tolerate 10 mg/kg i.v. as a bolus injection and had a maximum weight loss of 2%.
(DMSO) for i.p. and s.c. administration (Table 2). However, the EtOH/saline solution produced as high an MTD as did CMC/Tw suspension when administered as an i.v. bolus dose (20 mg/kg), with the exception of CD2F1 mice that could tolerate only 10 mg/kg cytochalasin B. In [19], we demonstrated that liposome-encapsulated cytochalasin B could dramatically increase the MTD of the agent when administered i.p. We have now demonstrated that liposome-encapsulated cytochalasin B increases the MTD of i.v. and s.c. administered cytochalasin B (20 to 25 mg/kg i.v. and 100 to >500 mg/kg s.c.). In addition, we demonstrated that liposome-encapsulated cytochalasin B can be safely administered i.p. at 400 mg/kg, an eight-fold higher dose than can be used with non-liposome-encapsulated cytochalasin B.

We have previously characterized the pharmacokinetics and tissue distribution of nonencapsulated and liposome-encapsulated cytochalasin B administered i.p [19,25]. The present study extended these analyses to i.v. nonencapsulated cytochalasin B. Although there has been concern that cytochalasin B could have potential cardiotoxicity in vivo [28,29], the relatively low tissue concentration of cytochalasin B found in this organ after i.v. bolus administration 0 to 24 hours postinjection (Figure 2 and Table 1), combined with the low rate of drug-related deaths at notably high drug concentrations of cytochalasin B using multiple routes of administration (Table 2), suggests that cytochalasin B does not elicit cardiotoxicity to any significant degree when administered as an i.v. bolus dose. This is important, as cytochalasin B has shown marked drug synergy with multiple nucleic acid–directed agents including doxorubicin [17], a member of the anthracycline drug class that is noted for substantial cardiotoxicity [30]. Therefore, the concomitant administration of cytochalasin B and anthracyclines remains a feasible combination for evaluating antineoplastic activity in murine models.
However, HPLC analysis of 3H-labeled cytochalasin B revealed that lipophilic blood brain barrier (BBB) in brain cancer chemotherapy might be considered for use as an i.v. administered agent to cross the BBB without having to be in direct contact with the tumor nodule [19], cytochalasin B can exert antitumor activity in M109 lung carcinoma can reach its intended target and remain in significant concentration after administration of 3.5 mg/kg. These data indicate that cytochalasin B found in malignant growths 12 hours after a single i.v. bolus injection is notable and may raise concern for potential pulmonary toxicity. Nevertheless, i.v. cytochalasin B was tolerated in suspension at 20 mg/kg as a bolus dose and increased to 25 mg/kg after liposome encapsulation. Therefore, it may be possible to combine cytochalasin B with nucleic acid encapsulation. Therefore, it may be possible to combine cytochalasin B with nucleic acid–directed agents that exhibit marked pulmonary toxicity, such as bleomycin [30], without subjecting tumor-bearing mice to intolerable side effects.

In addition to its concentration in normal tissue, it appears that i.v. cytochalasin B readily infiltrates neoplastic tissue, as demonstrated with M109 lung carcinoma (Figure 2B). The concentration of cytochalasin B in M109 tumor nodules leveled off between 180 and 720 minutes, indicating that sustained levels of the agent can be found in malignant growths 12 hours after a single i.v. bolus administration of 3.5 mg/kg. These data indicate that cytochalasin B can reach its intended target and remain in significant concentration hours after administration. Nevertheless, we have demonstrated that cytochalasin B can exert antitumor activity in M109 lung carcinoma without having to be in direct contact with the tumor nodule [19], and direct cytotoxicity may not be necessary for significant cytochalasin–mediated tumor regression.

Cytochalasin B is a notably lipophilic compound, suggesting that it might be considered for use as an i.v. administered agent to cross the lipophilic blood brain barrier (BBB) in brain cancer chemotherapy. However, HPLC analysis of 3H-labeled cytochalasin B revealed that the agent does not reach high tissue concentrations in the brain when administered i.v. (0.06 μg/g tissue 30 minutes after a 5.0-mg/kg dose). This is likely due to the relatively high molecular weight of cytochalasin B (MW = 479.6), as bulky compounds have difficulty traversing the BBB [30]. For comparison, the lipophilic alkylating agent temozolomide, which is known to readily cross the BBB, has an MW = 194.151. Nevertheless, these low concentrations of cytochalasin B may still exhibit notable in vivo antineoplastic activity against brain tumors, or it may be possible to administer cytochalasin B intrathetically into mammalian preclinical models to assess its efficacy against brain tumors. These studies are currently under way in our laboratory.

In [17–19], we demonstrated that cytochalasin B has marked antitumor activity in murine models challenged with solid localized tumors, as well as against disseminated cancers. In this study, we confirmed that cytochalasin B markedly affects the progression of M109 lung carcinoma (Figure 3A) and can produce long-term survival when administered i.v. or s.c. (8/16 mice treated i.v. were alive at 53 days, whereas 4/10 mice treated s.c. were alive at 53 days; Figures 3B and 4, respectively). These effects were comparable to doxorubicin administered once or twice as a 5-mg/kg i.p. dose (Figure 3), indicative of the marked antitumor activity elicited by cytochalasin B in the M109 tumor model system. In addition, it appears that cytochalasin B has marked cytotoxicity for metastatic cells, as the agent reduced the number of M109c lung metastases from a mean of 62 nodules when treated only with an EtOH/saline vehicle to a mean of 7 nodules when treated five times with 5-mg/kg cytochalasin B i.v. bolus (Figure 3C). The reduction of metastases was greater than 5 mg/kg doxorubicin i.p., which had a mean of 57 nodules with only one injection, and a mean of 50 nodules after two injections (Figure 3C). Further, the reduction in lung metastases potentiated by cytochalasin B appeared to be dose dependent, further confirming the antitumor activity the agent has toward metastatic cells. These effects on reduction in metastatic nodules are very similar to our observations in [17,18], indicating that cytochalasin B can inhibit metastatic progression in tumor-bearing murine models.

Although we have previously demonstrated the antitumor activity of cytochalasin B in vivo against M109 lung carcinoma, B16F10 melanoma, and P388/S and P388/ADR leukemia [17–19], we have now extended these observations to Lewis lung carcinoma and LA4 adenocarcinoma. These data suggest that cytochalasin B is notably active against murine lung cancers and that investigating its potential in human lung tumor xenograft models is warranted. It is also important to note that although cytochalasin B was able to prolong

![Figure 4. Effects of cytochalasin B administered once as a 100-mg/kg s.c. dose on potentiating long-term survival in mice challenged with various solid tumors. Mice were challenged i.d. with M109 lung carcinoma and s.c. with Lewis lung carcinoma, LA4 lung adenocarcinoma, B16F10 melanoma, or M6076 sarcoma. In each challenge, the survival of tumor-bearing mice treated with cytochalasin B (denoted by CB) was significantly different than the vehicle-only-treated group (denoted by V); P < .05, as assessed by a Cox-Mantel test. There were 10 mice for all cohorts.](image-url)
the life of mice challenged with M5076 sarcoma, the agent was unable to produce any long-term survivors at day 53. This is an initial indication of the type of malignancies that cytochalasin B may not be efficacious for, but certainly does not preclude its examination in other sarcoma models.

Previously, we have demonstrated that cytochalasin B has a marked increase in cytotoxicity in vitro against murine melanoma cells selected by in vivo serial passage for an increased propensity to metastasize [17]. When combined with our data on in vivo metastases reduction, it appears that metastatic cells are particularly sensitive to cytochalasin B. These observations are in accordance with the importance of microfilaments in motility and invasion [31,24,23,32,33]. Significantly inhibiting actin polymerization would likely inhibit the rate at which neoplastic cells metastasize and therefore highlights the potential utility of microfilament-disrupting agents in the clinical setting. The utility of cytochalasin B in antimetastatic therapy may extend further than inhibiting the motility of highly malignant cells, as demonstrated by the ability of the agent to disrupt the secretion of GlcNACase in B16BL6 and B16F10 melanoma cells (Table 3). GlcNACase and other glycosidases are used by metastatic cells to degrade the carbohydrate polymers that mask the protein backbone of the extracellular matrix, enabling nearby proteases to provide the physical space needed for malignant cell migration [34–37]. Inhibiting the secretion of glycosidases by metastatic cells would reduce the extent of carbohydrate degradation, thereby reducing the efficacy of proteases to clear a navigable path to the vasculature necessary for intravasation.

Conclusion
Cytochalasin B, its congeners, and other microfilament-directed agents comprise a potentially novel class of chemotherapeutic agents, as they have shown in vitro and in vivo efficacy against many forms of malignancy [1]. The method by which our laboratory extracts cytochalasins A and B from D. dematioides is provided so that other interested laboratories can evaluate and extend our findings and contribute additional preclinical evidence to warrant clinical examination. This method is cost effective and substantially decreases the expense of in vivo work involving cytochalasins A and B. To compare, a mate of D. dematioides can produce the gram quantities of cytochalasins A and B needed for extensive mammalian study for less than $400 (420 g dry mold produces ~700 mg cytochalasin B and 90 mg cytochalasin A). By contrast, 10 mg cytochalasin A and 50 mg cytochalasin B from a commercial supplier can cost around $633.00 and $1245.00, respectively. In addition, partial or total syntheses of cytochalasins have been described [38–40] and are another alternative to commercial purchases. Although it is true that most promising drug leads fail to exhibit clinical efficacy, microfilament-directed agents have yet to be critically evaluated in controlled clinical trials. Critical assessment of these novel antineoplastic agents is indeed warranted and hopefully will establish a new avenue of chemotherapy.

Acknowledgements
Animal studies were approved by an IACUC protocol. The authors declare no conflicts of interest.

References
[1] Trendowski M (1846). Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach. Biochim Biophys Acta 2, 599–616.

[2] Rao JY, Hurst RE, Bales WD, Jones PL, Bass RA, Archer LT, Bell PB, and Hemstreet III GP (1990). Cellular F-actin levels as a marker for cellular transformation: relationship to cell division and differentiation. Cancer Res 50(8), 2215–2220.

[3] Weinberg RA (2013). The Biology of Cancer. 2nd ed. Garland Science; 2013.

[4] Scherlach K, Boettger D, Remme N, and Hertweck C (2010). The chemistry and biology of cytochalasans. Nat Prod Rep 27(6), 869–886.

[5] Trendowski M (2015). Using cytochalasins to improve current chemotherapeutic approaches. Anticancer Agents Med Chem 15(3), 327–335.

[6] Van Goetsenoveng M, Mathieu V, Andolfi A, Cininno A, Lefrancois F, Kiss R, and Evidente A (2011). In vitro growth inhibitory effects of cytochalasins and derivatives in cancer cells. Planta Med 77(7), 711–717.

[7] Yahara I, Harada F, Sekita S, Yoshiiyama H, and Natori S (1982). Correlation between effects of 24 different cytochalasins on cellular structures and cellular events and those on actin in vitro. J Cell Biol 92(1), 69–78.

[8] Flanagan MD and Lin S (1980). Cytochalasins block actin filament elongation by binding to high affinity sites associated with F-actin. J Biol Chem 255(3), 835–838.

[9] MacLean-Fletcher S and Pollard TD (1980). Mechanism of action of cytochalasin B on actin. Cell 20(2), 329–341.

[10] Kelly F and Sambrook J (1973). Differential effect of cytochalasin B on normal and transformed mouse cells. Mol Biol 62(120), 217–219.

[11] Stein MR, Altenburg B, Richards CS, Dudley JP, Medina D, and Burde JS (1978). Differential response of cultured mouse mammary cells of varying tumorigenicity to cytochalasin B. Cancer Res 38(9), 2719–2721.

[12] Medina D, Oborn CJ, and Asch BB (1980). Distinction between preneoplastic and neoplastic mammary cell populations in vitro by cytochalasin B-induced multinucleation. Cancer Res 40(2), 329–333.

[13] Somers KD and Murphy MM (1982). Multinucleation in response to cytochalasin B: a common feature in several human tumor cell lines. Cancer Res 42(7), 2575–2578.

[14] Trendowski M, Yu G, Wong V, Acquafondata C, Christen T, and Fondy TP (2014). The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells. Anticancer Res 34(5), 2195–2202.

[15] O’Neill FJ (1975). Selective destruction of cultured tumor cells with uncontrolled nuclear division by cytochalasin B and cystine arabinoside. Cancer Res 35(11 Pt 1), 3111–3115.

[16] Kolber MA and Hill P (2014). Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro. Cancer Chemother Pharmacol 1992; 30(4): 286-290. Anticancer Res 34(5), 2195–2202.

[17] Trendowski M, Mitchell JM, Corsette CM, Acquafondata C, and Fondy TP (2015). Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs 33(2), 290–299.

[18] Bousquet PF, Pauslen LA, Fondy C, Lipski KM, Loucy KJ, and Fondy JP (1990). Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma. Cancer Res 50(5), 1431–1439.

[19] Trendowski M, Mitchell JM, Corsette CM, Acquafondata C, and Fondy TP (2015). Chemotherapy in vivo against murine M109 lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration. Invest New Drugs 33(2), 280–289.

[20] Yamazaki D, Kurisu S, and Takenawa T (2007). Regulation of cancer cell motility through actin reorganization. Cancer Sci 96(7), 379–386.

[21] Stevenson RP, Veltman D, and Machesky LM (2012). Actin-bundling proteins in cancer progression at a glance. Curr Cancer Drug Targets 12(5), 1073–1079.

[22] Lorente G, Syriani E, and Morales M (2014). Actin filaments at the leading edge of metastatic cells. J Cell Sci 127(1), 107–117.

[23] Yamazaki D, Kurisu S, and Takenawa T (2007). Regulation of cancer cell motility through actin reorganization. Cancer Sci 96(7), 379–386.

[24] Stevenson RP, Veltman D, and Machesky LM (2012). Actin-bundling proteins in cancer progression at a glance. Curr Cancer Drug Targets 12(5), 1073–1079.

[25] Stevenson RP, Veltman D, and Machesky LM (2012). Actin-bundling proteins in cancer progression at a glance. Curr Cancer Drug Targets 12(5), 1073–1079.

[26] Stevenson RP, Veltman D, and Machesky LM (2012). Actin-bundling proteins in cancer progression at a glance. Curr Cancer Drug Targets 12(5), 1073–1079.

[27] Stevenson RP, Veltman D, and Machesky LM (2012). Actin-bundling proteins in cancer progression at a glance. Curr Cancer Drug Targets 12(5), 1073–1079.
[29] Sachs HG, McDonald TF, and Springer M (1974). Cytochalasin B and embryonic heart muscle: contractility, excitability and ultrastructure. *J Cell Sci* 14(1), 163–185.

[30] Chabner BA and Longo DL (2011.). Cancer chemotherapy and biotherapy: principles and practice. 5th ed. Lipincott Williams & Wilkins; 2011.

[31] Mehlen P and Puisieux A (2006). Metastatic: a question of life or death. *Nat Rev Cancer* 6(6), 449–458.

[32] Hayot C, Debeir O, Van Ham P, Van Damme M, Kiss R, and Decaestecker C (2006). Characterization of the activities of actin-affecting drugs on tumor cell migration. *Toxicol Appl Pharmacol* 211(1), 30–40.

[33] Fenteany G and Zhu S (2003). Small-molecule inhibitors of actin dynamics and cell motility. *Curr Top Med Chem* 3(6), 593–616.

[34] Niedbala MJ, Madiyalakan R, Matta K, Crickard K, Sharma M, and Bernacki RJ (1987). Role of glycosidases in human ovarian carcinoma cell mediated degradation of subendothelial extracellular matrix. *Cancer Res* 47(17), 4634–4641.

[35] Woynarowska B, Wikiel H, and Bernacki RJ (1989). Human ovarian carcinoma beta-N-acetylglucosaminidase isoenzymes and their role in extracellular matrix degradation. *Cancer Res* 49(20), 5598–5604.

[36] Luqmani Y, Temmim M, Memon A, Abdulaziz L, Parkar A, Ali M, Baker H, Motawey M, and Fayaz S (1999). Measurement of serum N-acetyl beta glucosaminidase activity in patients with breast cancer. *Acta Oncol* 38(5), 649–653.

[37] Ramessur KT, Greenwell P, Nash R, and Dwek MV (2010). Breast cancer invasion is mediated by beta-N-acetylglucosaminidase (beta-NAG) and associated with a dysregulation in the secretory pathway of cancer cells. *Br J Biomed Sci* 67(4), 189–196.

[38] Stork G, Nakahara Y, Nakahara Y, and Greenlee WJ (1978). Total synthesis of cytochalasin B. *J Am Chem Soc* 100(24), 7775–7777.

[39] Fuji R, Minami A, Gomi K, and Oikawa H (2013). Biosynthetic assembly of cytochalasin backbone. *Tetrahedron Lett* 54(23), 2999–3002.

[40] Stork G and Nakamura E (1983). A simplified total synthesis of cytochalasins via an intramolecular Diels-Alder reaction. *J Am Chem Soc* 105(16), 5510–5512.